Cardio-Oncology Education and Training: JACC Council Perspectives

 

 

 

The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.

Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.

The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.

both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A

Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.

Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected.
Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.

Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.

 

 

Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population

Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.

Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.

Peptide YY (PYY) (3-36)-Gly (Human) - Antibody
H-059-08 100 μl
EUR 469.8
[Cys0]-Peptide YY (PYY) (3-19) (Human) - Antibody
H-059-16 100 μl
EUR 469.8
Gastrin Releasing Peptide (GRP) (Human) - Antibody
H-027-07 50 μl
EUR 238.68
[Cys20]-Peptide YY (PYY) (3-19) (Human) - Antibody
H-059-17 100 μl
EUR 469.8
Peptide YY (PYY) (Human) - Purified IgG Antibody
G-059-01 400 μg
EUR 438.48
Peptide-Depleted Plasma (Human)
MB-099-01 2 ml
EUR 119.88
Stresscopin Related Peptide (SRP) (Human) - Antibody
H-019-27 50 μl
EUR 604.8
Peptide YY (PYY) (3-36) (Human)
059-02 200 μg
EUR 102.6
C28 optimized peptide 6 (Human)
073-82 100 μg
EUR 235.44
Anti-Inflammatory Peptide 1
004-01 200 μg
EUR 27
Anti-Inflammatory Peptide 2
004-02 200 μg
EUR 27
Anti-Inflammatory Peptide 3
004-03 200 μg
EUR 27
Peptide YY (PYY) (Human) - EIA Kit
EK-059-01 96 wells
EUR 617.76
Peptide YY (PYY) (Human) - RIA Kit
RK-059-01 125 tubes
EUR 814.32
Galanin-Like Peptide (GALP) (36-60) (Human) - Antibody
H-026-55 50 μl
EUR 604.8
Galanin-Like Peptide (GALP) (Human)
026-51 100 μg
EUR 230.04
PACAP-Related Peptide (PRP) (Human)
052-10 200 μg
EUR 86.4
Anti-Angiogenic Peptide Library
L-008A 88 peptides
EUR 6067.44
T3 Peptide / Tumstatin (69-88) (Human)
016-50 100 μg
EUR 255.96
T7 Peptide / Tumstatin (74-98) (Human)
016-51 100 μg
EUR 255.96
Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Antibody
H-008-50 50 μl
EUR 604.8
Peptide YY (PYY) (3-36) (Human) - Purified IgG Antibody
G-059-02 200 μg
EUR 604.8
Gastrin Releasing Peptide (GRP) (Human)
027-07 200 μg
EUR 119.88
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody
G-064-07 400 μg
EUR 438.48
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human)
064-07 200 μg
EUR 114.48
Peptide YY (PYY) (1-36)-Gly (Human)
059-07 100 μg
EUR 295.92
Peptide YY (PYY) (3-36)-Gly (Human)
059-08 100 μg
EUR 282.96
Peptide YY (PYY) (2-36)-Gly (Human)
059-11 100 μg
EUR 267.84
Peptide YY (PYY) (4-36)-Gly (Human)
059-12 100 μg
EUR 267.84
Stresscopin Related Peptide (SRP) (Human)
019-27 100 μg
EUR 214.92
SHAAG Peptide / Chemokine (46-63) (Human)
072-32 100 μg
EUR 160.92
RFamide-Related Peptide 3 (RFRP-3) (Human) - Antibody
H-048-46 100 μl
EUR 604.8
Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human)
072-17 100 μg
EUR 370.44
Fractalkine Chemokine Domain peptide (41-52) (Human)
026-82 200 μg
EUR 160.92
Fractalkine Chemokine Domain peptide (53-60) (Human)
026-83 200 μg
EUR 135
Fractalkine Chemokine Domain peptide (60-71) (Human)
026-84 200 μg
EUR 160.92
Urotensin II Related Peptide (Human, Rat, Mouse) - Antibody
H-071-17 50 μl
EUR 604.8
Osteoblast Activating Peptide (OBAP) (Human)
055-52 100 μg
EUR 199.8
Human Proteome Signature Peptide Library
L-010 98 peptides
EUR 7804.08
C28 optimized peptide 15 Dimer (Human)
073-86 100 μg
EUR 420.12
Nesfatin-1-Like Peptide (NLP) (Human)
009-83 100 μg
EUR 469.8
APP 17mer peptide / APP770 (204-220) (Human)
018-74 100 μg
EUR 135
Galanin-Like Peptide (GALP) (Human) - Purified IgG Antibody
G-026-51 200 μg
EUR 604.8
C28 optimized peptide 15 Monomer (Human)
073-84 100 μg
EUR 258.12
Peptide YY (PYY) (3-36) (Human) - EIA Kit
EK-059-02 96 wells
EUR 617.76
Peptide YY (PYY) (3-36) (Human) - RIA Kit
RK-059-02 125 tubes
EUR 814.32
Peptide YY (PYY) (Human) - I-125 Labeled
T-059-01 10 μCi
EUR 1145.88
SHLP1 / Small Humanin-Like Peptide 1 (Human)
018-75 100 μg
EUR 263.52
SHLP2 / Small Humanin-Like Peptide 2 (Human)
018-76 100 μg
EUR 263.52
SHLP3 / Small Humanin-Like Peptide 3 (Human)
018-77 100 μg
EUR 422.28
SHLP4 / Small Humanin-Like Peptide 4 (Human)
018-78 100 μg
EUR 289.44
SHLP5 / Small Humanin-Like Peptide 5 (Human)
018-79 100 μg
EUR 316.44
SHLP6 / Small Humanin-Like Peptide 6 (Human)
018-80 100 μg
EUR 250.56
Gastrin Releasing Peptide (GRP) (Human) - Purified IgG Antibody
G-027-07 400 μg
EUR 438.48
Agouti-Related Peptide (AgRP) (83-132) amide (Human) - Antibody
H-003-53 50 μl
EUR 469.8
Galanin-Like Peptide (GALP) (36-60) (Human)
026-55 200 μg
EUR 177.12
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit
RK-064-07 125 tubes
EUR 932.04
FGF23 (188-199 )optimized peptide 10 (Human)
073-88 100 μg
EUR 258.12
Stresscopin Related Peptide (SRP) (Human) - Purified IgG Antibody
G-019-27 200 μg
EUR 604.8
Prolactin-Releasing Peptide-31 (PrRP-31) (Human)
008-50 200 μg
EUR 199.8
Prolactin-Releasing Peptide-20 (PrRP-20) (Human)
008-51 200 μg
EUR 199.8
Peptide YY (PYY) (3-36) (Human) - FAM Labeled
FG-059-02A 1 nmol
EUR 336.96
Agouti-Related Peptide (AgRP) (25-51) (Human)
003-51 200 μg
EUR 129.6
Agouti-Related Peptide (AgRP) (54-82) (Human)
003-52 200 μg
EUR 129.6
Agouti-Related Peptide (AgRP) (25-82) (Human)
003-74 100 μg
EUR 497.88
Gastrin Releasing Peptide (GRP) (18-27) (Human)
027-41 200 μg
EUR 160.92
Seminal Plasma Inhibin-Like Peptide (Human)
034-03 200 μg
EUR 194.4
Gastrin Releasing Peptide (GRP) (1-16) (Human)
027-08 1 mg
EUR 177.12
Gastrin Releasing Peptide (GRP) (1-17) (Human)
027-42 200 μg
EUR 189
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled
FG-064-07A 1 nmol
EUR 336.96
Galanin-Like Peptide (GALP) (Human) - RIA Kit
RK-026-51 125 tubes
EUR 932.04
Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Purified IgG Antibody
G-008-50 400 μg
EUR 604.8
Galanin-Like Peptide (GALP) (36-60) (Human) - Purified IgG Antibody
G-026-55 200 μg
EUR 604.8
[Tyr0]-pro-Gastrin Releasing Peptide (GRP) (80-97) (Human) - Antibody
H-027-36 100 μl
EUR 370.44
Peptide YY (PYY) (3-36) (Human) - Biotin Labeled
B-059-02 10 μg
EUR 405
RFamide-Related Peptide 1 (RFRP-1) (Human)
048-42 500 μg
EUR 177.12
RFamide-Related Peptide 2 (RFRP-2) (Human)
048-44 500 μg
EUR 177.12
RFamide-Related Peptide 3 (RFRP-3) (Human)
048-46 500 μg
EUR 177.12
Gastrin Releasing Peptide (GRP) (Human) - EIA Kit
EK-027-07 96 wells
EUR 603.72
Gastrin Releasing Peptide (GRP) (Human) - RIA Kit
RK-027-07 125 tubes
EUR 932.04
Urotensin II Related Peptide (Human, Rat, Mouse)
071-17 200 μg
EUR 129.6
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled
T-064-07 10 μCi
EUR 1145.88
T3 Peptide / Tumstatin (69-88) (Human) - FAM Labeled
FG-016-50A 1 nmol
EUR 469.8
T7 Peptide / Tumstatin (74-98) (Human) - FAM Labeled
FG-016-51A 1 nmol
EUR 469.8
Galanin-Like Peptide (GALP) (Human) - FAM Labeled
FG-026-51A 1 nmol
EUR 604.8
Stresscopin Related Peptide (SRP) (Human) - RIA Kit
RK-019-27 125 tubes
EUR 1341.36
Peptide YY (PYY) (3-36) (Human) - I-125 Labeled
T-059-02 10 μCi
EUR 1145.88
Peptide YY (PYY) (3-36) (Human) - Rhodamine Labeled
FR-059-02 1 nmol
EUR 405
Peptide YY (PYY) (3-36) (Human) - MagBead (Magnetic Bead Linked Antibody)
MB-059-02 1 ml
EUR 842.4
Gastrin Releasing Peptide-Gly (GRP-Gly) (Human)
027-37 100 μg
EUR 160.92
[Tyr0]-Agouti-Related Peptide (AgRP) (25-51) (Human)
003-72 100 μg
EUR 416.88
[Tyr0]-Agouti-Related Peptide (AgRP) (54-82) (Human)
003-73 100 μg
EUR 416.88
prepro-RFamide Related Peptide (RFRP) (56-92) amide (Human) - Antibody
H-048-54 100 μl
EUR 604.8
prepro-RFamide Related Peptide (RFRP) (115-131) amide (Human) - Antibody
H-048-55 50 μl
EUR 604.8
R3 (BDelta23-27) R / I5 Chimeric Peptide (Human)
035-66 100 μg
EUR 604.8
Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit
RK-009-83 125 tubes
EUR 980.64
7B2 Carboxyl-terminal (CT) peptide (Human, Porcine)
004-32 100 μg
EUR 160.92
Osteoblast Activating Peptide (OBAP) (Human) - EIA Kit
EK-055-52 96 wells
EUR 660.96
Osteoblast Activating Peptide (OBAP) (Human) - RIA Kit
RK-055-52 125 tubes
EUR 980.64
pro-Gastrin Releasing Peptide (GRP) (42-98) (Human)
027-34 100 μg
EUR 355.32
pro-Gastrin Releasing Peptide (GRP) (47-68) (Human)
027-35 100 μg
EUR 160.92
SHAAG Peptide / Chemokine (46-63) (Human) - Cy3 Labeled
FC3-072-32 1 nmol
EUR 587.52
SHAAG Peptide / Chemokine (46-63) (Human) - Cy5 Labeled
FC5-072-32 1 nmol
EUR 587.52
SHAAG Peptide / Chemokine (46-63) (Human) - FAM Labeled
FG-072-32A 1 nmol
EUR 267.84
Agouti-Related Peptide (AgRP) (71-132), Form C amide (Human) - Antibody
H-003-55 50 μl
EUR 604.8
Stresscopin Related Peptide (SRP) (Human) - FAM Labeled
FG-019-27A 1 nmol
EUR 537.84
prepro-Galanin-Like Peptide (GALP) (87-116) (Human)
026-54 200 μg
EUR 230.04
Urotensin II Related Peptide (Human, Rat, Mouse) - Purified IgG Antibody
G-071-17 200 μg
EUR 604.8
Peptide YY (PYY) (3-36) (Human) - Fluorescent EIA Kit
FEK-059-02 96 wells
EUR 660.96
Agouti-Related Peptide (AgRP) (83-132) amide (Human)
003-53 100 μg
EUR 316.44
[Leu(13C)6,(15N)-15,22]-Peptide YY (PYY) (3-36) (Human)
SIL-059-02 20 μg
EUR 1186.92
Gastrin Releasing Peptide (GRP) (14-27) (Human, Porcine)
027-16 500 μg
EUR 108
Prostate Specific Antigen (PSA) (243-261) / C-terminal PSA peptide (Human)
034-45 100 μg
EUR 199.8
[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human)
048-43 200 μg
EUR 177.12
[Tyr0]-RFamide-Related Peptide 2 (RFRP-2) (Human)
048-45 200 μg
EUR 177.12
[Tyr0]-RFamide-Related Peptide 3 (RFRP-3) (Human)
048-47 200 μg
EUR 177.12
Galanin-Like Peptide (GALP) (Human) - Rhodamine Labeled
FR-026-51 1 nmol
EUR 604.8
Parathyroid Hormone-Like Peptide (PLP) (140-173) (Human)
056-17 200 μg
EUR 129.6
SHAAG Peptide / Chemokine (46-63) (Human) - Biotin Labeled
B-072-32 10 μg
EUR 267.84
Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - EIA Kit
EK-008-50 96 wells
EUR 603.72
Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - RIA Kit
RK-008-50 125 tubes
EUR 932.04
Galanin-Like Peptide (GALP) (Human) - I-125 Labeled
T-026-51 10 μCi
EUR 1145.88

Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.

https://www.AffiAB.com
https://www.AffiASSAY.com
https://www.AffiCHECK.com
https://www.AffiCLONE.com
https://www.AffiCLEAN.com
https://www.AffiDETECT.com
https://www.AffiDYE.com
https://www.AffiELISA.com Kits
https://www.AffiEXTRACT.com
https://www.AffiNEURO.com
https://www.AffiNGS.com
https://www.AffiPCR.com
https://www.AffiPREP.com
https://www.AffiPURE.com
https://www.AffiREC.com
https://www.AffiSHIELD.com
https://www.AffiSTAIN.com
https://www.AffiVET.com